title: Toward a definition of pharmaceutical innovation.
abstract: ONGOING DEBATES IN THE PHARMACEUTICAL SECTOR ABOUT INTELLECTUAL PROPERTY, PRICING AND REIMBURSEMENT, AND PUBLIC RESEARCH INVESTMENTS HAVE A COMMON DENOMINATOR: the pursuit of innovation. However, there is little clarity about what constitutes a true pharmaceutical innovation, and as a result there is confusion about what kind of new products should be pursued, protected and encouraged through health policy and clinical practice. If the concept of pharmaceutical innovation can be clarified, then it may become easier for health policy-makers and practitioners to evaluate, adopt and procure products in ways that appropriately recognize, encourage and give priority to truly valuable pharmaceutical innovations.
authors: Steven
authors: S
authors: Morgan
authors: Ruth
authors: R
authors: Lopert
authors: Devon
authors: D
authors: Greyson
references: JAMA. 2005 Oct 26;294(16):2075-82
references: 16249422
references: BMJ. 2005 Oct 8;331(7520):815-6
references: 16141448
references: Lancet. 2002 Jun 22;359(9324):2188-94
references: 12090998
references: J Clin Pharmacol. 1980 Jan;20(1):1-9
references: 7358865
references: J Nephrol. 1997 Nov-Dec;10(6):283-94
references: 9442441
references: BMJ. 2002 Aug 3;325(7358):269-71
references: 12153927
references: JAMA. 1999 Aug 25;282(8):771-8
references: 10463714
references: Lancet. 2001 Dec 1;358(9296):1893-5
references: 11741648
references: Bull World Health Organ. 2006 May;84(5):414-6
references: 16710555
references: BMJ. 2005 Oct 15;331(7521):895-7
references: 16223825
references: J Clin Pharmacol. 1980 Feb-Mar;20(2-3):77-90
references: 7381029
references: Prescrire Int. 2001 Apr;10(52):52-4
references: 11718161